EX-99.1 2 exhibit991historicalrecast.htm EX-99.1 Document


Exhibit 99.1
PERRIGO COMPANY PLC
SELECT SEGMENT INFORMATION
QUARTERS AND FISCAL YEARS TO DATE 2025 and 2024
(in millions)
(unaudited)

Three Months EndedTwelve Months Ended
March 29, 2025June 28, 2025September 27, 2025December 31, 2025December 31, 2025
Net Sales
Self Care $614.3 $598.6 $633.1 $687.6 $2,533.5 
Specialty Care 199.1 233.1 191.2 176.0 799.3 
Infant Formula 87.8 82.0 89.3 99.9 359.0 
Total Segments Net Sales $901.2 $913.6 $913.6 $963.4 $3,691.8 
All Other 142.7 142.7 129.7 146.2 561.3 
Consolidated Net Sales $1,043.9 $1,056.3 $1,043.3 $1,109.6 $4,253.1 


Three Months EndedTwelve Months Ended
Net Sales March 30, 2024June 29, 2024September 28, 2024December 31, 2024December 31, 2024
Self Care $627.7 $600.5 $637.6 $688.6 $2,554.3 
Specialty Care 208.7 220.2 188.3 179.5 796.6 
Infant Formula 74.3 74.9 115.4 132.4 397.0 
Total Segments Net Sales $910.7 $895.6 $941.3 $1,000.4 $3,747.9 
All Other 171.5 170.0 146.3 137.8 625.6 
Consolidated Net Sales $1,082.1 $1,065.5 $1,087.5 $1,138.3 $4,373.4 

Note: Amounts may not add or recalculate due to rounding.










Exhibit 99.1

PERRIGO COMPANY PLC
SELECT SEGMENT INFORMATION
QUARTERS AND CALENDAR YEAR TO DATE 2025
(in millions)
(unaudited)
Three Months Ended Twelve Months Ended
Continuing Operations March 29,
2025		June 28,
2025		September 27, 2025December 31, 2025December 31,
2025
Segment adjusted operating income:
Self Care $112.8 $93.8 $130.6 $135.3 $472.6 
Specialty Care 42.1 66.3 42.1 50.0 200.5 
Infant Formula 10.6 (12.2)14.6 (3.4)9.6 
Total segment adjusted operating income$165.5 $147.9 $187.3 $181.9 $682.6 
All Other21.0 25.7 22.5 24.2 93.4 
Unallocated (39.9)(38.5)(36.4)(38.9)(153.7)
Consolidated adjusted operating income $146.6 $135.2 $173.4 $167.2 $622.3 



Note: Amounts may not add or recalculate due to rounding.

















Exhibit 99.1


PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
SELECT CONSOLIDATED INFORMATION
QUARTERS AND CALENDAR YEAR TO DATE 2025
(in millions)
(unaudited)
Three Months Ended Twelve Months Ended
Consolidated Continuing OperationsMarch 29,
2025		June 28,
2025		September 27, 2025December 31, 2025December 31,
2025
Reported Operating Income (Loss) $46.9 $45.4 $72.6 $(1,287.2)$(1,122.2)
Pre-tax adjustments:
Amortization expense related primarily to acquired intangible assets 55.0 56.8 56.0 55.7 223.5 
Unusual litigation8.9 15.4 15.0 19.7 59.0 
Restructuring charges and other termination benefits 29.4 8.7 20.9 13.0 71.9 
Impairment charges (1)
3.1 1.5 — 1,358.5 1,363.1 
Infant formula remediation0.9 — — — 0.9 
Other(2)
2.4 7.4 8.9 7.4 26.1 
Consolidated adjusted operating income $146.6 $135.2 $173.4 $167.2 $622.3 

Note: Amounts may not add or recalculate due to rounding.

(1) During the three months ended March 29, 2025, we determined the carrying value of the Richard Bittner Business net assets held for sale exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million, inclusive of a goodwill impairment charge of $1.2 million. During the three months ended June 28, 2025, we determined the carrying value of our Prevacid® branded product was impaired by $1.5 million. During the three months ended December 31, 2025, we determined the carrying value of our reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of $1.3 billion and the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million.
(2) Other pre-tax adjustments for the three months ended March 29, 2025 are related to professional consulting fees for potential divestiture activity. Other pre-tax adjustments for the three months ended June 28, 2025 are primarily related to $4.5 million of accelerated depreciation as a result of our Nutrition Network Optimization Project and $2.8 million of professional consulting fees for divestiture activity. Other pre-tax adjustments for the three months ended September 27, 2025 includes $4.2 million of accelerated depreciation and a $1.6 million asset abandonment related to our Nutrition Network Optimization Project and $3.1 million of professional consulting fees for divestiture activity. Other pre-tax adjustments for the three months ended December 31, 2025 includes $3.8 million of professional consulting fees for potential divestiture activity and $3.2 million of accelerated depreciation.